These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9578139)

  • 1. Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats.
    Valverde O; Roques BP
    Neurosci Lett; 1998 Mar; 244(1):37-40. PubMed ID: 9578139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats.
    Wen D; Sun D; Zang G; Hao L; Liu X; Yu F; Ma C; Cong B
    Neuroscience; 2014 Sep; 277():14-25. PubMed ID: 24993476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
    Boyle SJ; Tang KW; Woodruff GN; McKnight AT
    Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats.
    Lu L; Huang M; Liu Z; Ma L
    Neuroreport; 2000 Mar; 11(4):829-32. PubMed ID: 10757528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Several roles of CCKA and CCKB receptor subtypes in CCK-8-induced and LiCl-induced taste aversion conditioning.
    Mosher JT; Johnson MF; Birkemo LS; Ervin GN
    Peptides; 1996; 17(3):483-8. PubMed ID: 8735976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol.
    Higgins GA; Joharchi N; Wang Y; Corrigall WA; Sellers EM
    Brain Res; 1994 Mar; 640(1-2):246-54. PubMed ID: 8004452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
    Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT
    Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of CCK-B receptors involved in animal models of anxiety.
    Derrien M; McCort-Tranchepain I; Ducos B; Roques BP; Durieux C
    Pharmacol Biochem Behav; 1994 Sep; 49(1):133-41. PubMed ID: 7816864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
    Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor subsites.
    Léna I; Roques BP; Durieux C
    J Neurochem; 1997 Jan; 68(1):162-8. PubMed ID: 8978722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of CCKB/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat.
    Hayward NJ; Harding M; Lloyd SA; McKnight AT; Hughes J; Woodruff GN
    Br J Pharmacol; 1991 Dec; 104(4):973-7. PubMed ID: 1687371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential modulation of alpha 2-adrenergic and opioid spinal antinociception by cholecystokinin and cholecystokinin antagonists in the rat dorsal horn: an electrophysiological study.
    Sullivan AF; Hewett K; Dickenson AH
    Brain Res; 1994 Oct; 662(1-2):141-7. PubMed ID: 7859067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats.
    Lemaire M; Böhme GA; Piot O; Roques BP; Blanchard JC
    Psychopharmacology (Berl); 1994 Aug; 115(4):435-40. PubMed ID: 7871086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
    Crawley JN
    J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity.
    Jagerschmidt A; Guillaume-Rousselet N; Vikland ML; Goudreau N; Maigret B; Roques BP
    Eur J Pharmacol; 1996 Jan; 296(1):97-106. PubMed ID: 8720482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats.
    Maldonado R; Valverde O; Derrien M; Tejedor-Real P; Roques BP
    Pharmacol Biochem Behav; 1994 Jun; 48(2):363-9. PubMed ID: 8090802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin A receptor antagonist inhibits feed memory in Japanese quail.
    Berthelot V; Belzung C; Meunier-Salaun MC; Nowak R; Picard M
    Physiol Behav; 1996 Aug; 60(2):575-9. PubMed ID: 8840921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of exogenous cholecystokinin octapeptide on acquisition of naloxone precipitated withdrawal induced conditioned place aversion in rats.
    Yu H; Wen D; Ma C; Meng Y; Li S; Ni Z; Cong B
    PLoS One; 2012; 7(7):e41860. PubMed ID: 22848639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of cholecystokinin to precipitate withdrawal in morphine-treated rats.
    Pournaghash S; Riley AL
    Pharmacol Biochem Behav; 1991 Mar; 38(3):479-84. PubMed ID: 2068185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.
    Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN
    Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.